Since the release of dupilumab for atopic dermatitis, studies are currently underway to investigate dupilumab for nasal polyps, asthma and a host of other conditions. Dupilumab is a human monoclonal antibody against interleukin 4 and 13. A study published in JAMA titled “Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis […]
Hypereosinophilia (elevated eosinophil count)
Hypereosinophilia or an elevated eosinophil count can have multiple causes. The differential list includes asthma, atopic disease, drug hypersensitivity, parasitic infections, connective tissue disorders, malignancy (cancer) and rare hypereosinophilic disorders. Hypereosinophilia is defined a blood eosinophil count greater than 1500 per microliter of blood and end organ damage attributable to eosinophilia. A count of greater […]
Lebrikizumab for the Treatment of Asthma (and Eczema)
Lebrikizumab is a new potential medication that could be used to treat severe asthma. The field of asthma is seeing a new surge of biologic medications, recently approved Nucala (mepolizumab) Nucala and potentially Cinquil (reslizumab) Cinquil. Both of those medications target IL-5, a driver for eosinophils. Lebrikizumab, is a humanized monoclonal antibody that targets IL-13, which will be […]